Risk Assessment for Stent Stenosis and New Coronary Disease
Risk Factors and Protective Features
- The American Heart Association suggests that LAD stent location is independently associated with higher restenosis rates (OR 3.0, p<0.04) 1, 2, 3
- The American College of Cardiology identifies hypertension as a risk factor for restenosis after percutaneous intervention 1, 3
- The European Society of Cardiology notes that excellent LDL control (less than 70 mg/dL) is recommended for very high-risk patients, and an Apolipoprotein B level of 65 is within optimal range for cardiovascular risk reduction 4
- The American Heart Association states that diabetes is a major risk factor for stent restenosis, but this patient has no diabetes 1, 3
Quantitative Risk Estimates
- The American College of Cardiology estimates that the baseline restenosis rate for bare metal stents is 17-32% in the first 2 years 1, 3
- The European Society of Cardiology suggests that the 5-year survival rate with 1-vessel LAD disease is approximately 95% 5
Clinical Implications
- The American Heart Association recommends symptom monitoring, and any recurrence of angina, dyspnea, or anginal equivalents warrants prompt evaluation 6
- The American College of Cardiology suggests considering periodic stress testing (every 2-3 years or with symptom changes) given high-risk anatomy (LAD stents) 5, 6
- The European Society of Cardiology recommends continuing dual antiplatelet therapy (aspirin 75-100 mg plus clopidogrel 75 mg daily) indefinitely given established CAD and stent history 7, 4
- The American Heart Association advises maintaining excellent LDL control through high-intensity statin therapy and targeting blood pressure control to less than 130/80 mmHg 4